Single source: Childhood Cancer Survivor Study (U24 Clinical Trial Not Allowed)

The National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, is a leading federal agency dedicated to cancer research and training. In alignment with its mission to reduce the burden of cancer, the NCI supports critical research programs such as the Childhood Cancer Survivor Study (CCSS). This study has provided an extensive, multi-institutional research infrastructure to understand the long-term outcomes associated with pediatric and adolescent cancer treatments. With over 38,000 long-term survivors enrolled and a comparative sibling cohort, the CCSS represents a valuable resource for the cancer research community. This Notice of Funding Opportunity (NOFO), RFA-CA-26-011, is a forecasted, non-competitive solicitation for a single cooperative agreement award. The primary objective is to continue funding the existing recipient of the CCSS to further expand the study's data and research potential. The continuation will emphasize longitudinal data collection on aging survivors and integrate pediatric patients treated with more modern therapeutic regimens. The study will serve both as a long-term data repository and as an active platform for conducting observational and interventional research focused on survivorship outcomes. The scope of work under this opportunity includes maintaining and expanding data infrastructure, enrolling new survivors, collecting biospecimens, and enhancing data sharing capacities for researchers. Key research objectives include evaluating late effects of cancer therapy, identifying risk factors for adverse outcomes, and informing evidence-based survivorship care practices. Though the funding amount is not disclosed in the forecast, the nature of the single-source cooperative agreement implies a tailored, substantial investment by the NCI to maintain continuity in this critical longitudinal research. The funding does not require cost sharing or matching, and is restricted to a single eligible recipient—namely, the current grantee managing the CCSS. This ensures consistency in data quality and stewardship of the longitudinal dataset. Eligible applicants are therefore not broadly defined beyond 501(c)(3) nonprofit status; this NOFO is intended specifically for the incumbent grantee organization. The anticipated timeline begins with a projected post date of June 22, 2026, and applications will be due by September 25, 2026. Awards are expected to be issued by July 1, 2027, with projects also beginning on that date. The application process will follow NIH’s standard peer review procedures, and only meritorious applications will be considered for the award, despite the single-source nature of the solicitation. No separate pre-application deadlines are specified, and the process does not include a required Letter of Intent or concept paper stage. For questions regarding this funding opportunity, applicants are directed to contact the National Cancer Institute via the designated program email listed as "NCI CCSS RFA." As a single-source forecasted opportunity, this grant does not recur on a predictable schedule, though the nature of the study implies long-term support. Further details, including full application requirements and guidance, will be available upon release of the official NOFO.